Early Detection of Pancreatic Adenocarcinoma (PDAC) Using a Panel of Biomarkers (UroPanc)
概览
- 阶段
- 不适用
- 干预措施
- Individuals at risk of developing PDAC
- 疾病 / 适应症
- Pancreatic Ductal Adenocarcinoma
- 发起方
- Queen Mary University of London
- 入组人数
- 3500
- 试验地点
- 4
- 主要终点
- Accuracy of biomarker panel and affiliated risk score
- 状态
- 招募中
- 最后更新
- 3个月前
概览
简要总结
Urine and blood samples are being collected from patients with and without diseases of the pancreas. These samples will be tested with the aim of developing an accurate way of diagnosing diseases of the pancreas using the results.
详细描述
The main aim of this research study is to establish the accuracy of a urinary biomarker panel (LYVE1, REG1B, TFF1), and affiliated PancRISK score alone or in combination with plasma CA19-9 for early detection of pancreatic ductal adenocarcinoma (PDAC). Samples will be collected from symptomatic individuals with suspected pancreatic cancer, and asymptomatic subjects at risk of developing PDAC. The results of urine biomarker and CA19-9 analysis carried out on these samples will be compared to the imaging and, where available, histopathology data, which will inform the development of a predictive model to detect PDAC earlier.
研究者
入排标准
入选标准
- •(Symptomatic patients):
- •Able and willing to give informed consent
- •≥18 years old
- •Suspected pancreatic diseases with symptoms including, but not limited to, diarrhoea, back pain, abdominal pain, nausea, vomiting, constipation or new onset diabetes
排除标准
- •(Symptomatic patients):
- •Current or prior treatment (chemotherapy, radiotherapy, surgical resection, biological therapy, and immunotherapy) for any malignancy other than basal cell carcinoma within 5 years of enrolment.
- •Asymptomatic participants will be identified through the EUROPAC registry and will fulfil EUROPAC's eligibility criteria.
研究组 & 干预措施
Individuals at risk of developing PDAC
* Symptomatic participants (via direct recruitment to UroPanc and via study/tissue bank(s) i.e. UCL ADEPTs study) * Asymptomatic participants (via study/tissue bank(s) i.e. University of Liverpool EUROPAC registry) Medical history, demographic information and concomitant medications information will be collected at baseline, together with blood and urine samples. Urinary biomarkers and plasma CA19-9 will be measured and the results compared with imaging data (and pathology, if it becomes available).
结局指标
主要结局
Accuracy of biomarker panel and affiliated risk score
时间窗: Baseline until completion of standard-of-care diagnostic testing (up to 12 months after enrolment)
Test accuracy, as measured by sensitivity/specificity (SN/SP) and positive predictive value/negative predictive value (PPV/NPV).
次要结局
- Economic and social impact of using biomarker panel for PDAC testing(Baseline until completion of standard-of-care diagnostic testing (up to 12 months after enrolment))
- Accuracy of biomarker panel and affiliated risk score when combined with CA19-9 result(Baseline until completion of standard-of-care diagnostic testing (up to 12 months after enrolment))